Beta Bionics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBNX research report →
Range $16 – $30
Price Chart
About the company
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older.
- CEO
- Sean T. Saint
- IPO
- 2025
- Employees
- 422
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on BBNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $601.06M
- P/E
- -7.12
- PEG
- 1.03
- P/S
- 4.71
- P/B
- 1.54
- EV/EBITDA
- -6.30
- Div Yield
- 0.00%
- Gross Margin
- 58.63%
- Op Margin
- -72.75%
- Net Margin
- -65.31%
- ROE
- -27.33%
- ROIC
- -22.45%
Latest fiscal year · YoY change
- Revenue
- $100.25M+53.9%
- Gross Profit
- $55.54M+54.8%
- Op Income
- $-71,681,000
- Net Income
- $-73,200,000-33.7%
- EPS
- $-1.81-41.4%
- OCF Growth
- -5.5%
- FCF Growth
- -8.8%
- 52W High
- $32.71
- 52W Low
- $8.80
- 50D MA
- $18.17
- 200D MA
- $14.82
- Beta
- 3.43
- RSI (14)
- 35
- Avg Volume
- 1.20M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Beta Bionics posted record Q3 sales growth and improved margins, while emphasizing Mint’s FDA clearance and a crowded but promising 2027 pipeline.· October 27, 2026
- Q3 net sales hit a record $35.5 million, up about 30% year over year, with gross margin at 57.3% and up 179 basis points versus last year.
- Management raised full-year 2026 revenue guidance to $124 million-$126 million from $121 million-$126 million, driven by a smaller-than-expected fourth-quarter Mint deferral impact.
- Mint received FDA clearance in September and is still expected to be fully commercialized in the U.S. in Q1 2027; the company raised about $161 million net in a public offering to support the launch.
- 3D Intelligence was delayed after the FDA asked the company to withdraw and resubmit its 510(k), but management said the issue was about simulator validation, not the algorithm itself.
- Pharmacy-channel mix remains an important growth driver, with new patient starts in the high 30s percent through pharmacy and full-year pharmacy mix guidance reiterated at 37%-39%.
Q3 2026 net sales were a record $35.5 million, up approximately 30% year over year. Gross margin was 57.3%, up 179 basis points year over year but down 178 basis points sequentially, mainly because of unfavorable mix from lower DME iLet revenue and distributor stocking dynamics. Total operating expenses were $46.9 million, up 46% year over year. As of September 30, 2026, the company had approximately $374 million in cash, cash equivalents, and short- and long-term investments. For full-year 2026, Beta Bionics raised revenue guidance to $124 million-$126 million, expects Q4 revenue of $29 million-$31 million, reiterated pharmacy mix of 37%-39%, and kept gross margin guidance at 58.5%-59.5%. Management said the potential Q4 revenue deferral from prospective Mint users is now expected to be up to $8.5 million, versus up to $10 million previously.
Sean Saint framed the quarter as a milestone period, calling Mint the company’s biggest product step yet and saying it was cleared by FDA in about three years, which he described as the fastest timeline he knows of for an AID patch pump. His tone was upbeat and highly confident on Mint, 3D Intelligence, fully closed loop, and type 2 expansion, repeatedly emphasizing that the company is building a broader diabetes technology platform rather than a single product. He also stressed that Mint’s product design, user experience, and manufacturing plans position Beta Bionics to compete differently in 2027.
Stephen Feider focused on the financial drivers behind the quarter and the updated outlook. He said Q3 revenue was driven by new patient starts and recurring pharmacy supply revenue, while gross margin of 57.3% was pressured by a lower contribution from high-margin DME iLet revenue because distributors ended the quarter with lower iLet inventory; he said that mix should normalize in Q4. He noted operating expenses were $46.9 million, cash was approximately $374 million, and the public offering was meant to fund Mint manufacturing capex and strengthen the balance sheet. He also reiterated full-year gross margin guidance of 58.5%-59.5% and said the company expects positive free cash flow well ahead of historical diabetes peers.
Most of the Q&A centered on 3D Intelligence and Mint adoption. Management said the 3D delay was due to FDA questions about simulator validation and documentation, not the algorithm’s results or any human-factors issue, and said a late-2026 clearance is technically still possible, though next year is the base case. On Mint, they said first commercial shipments are expected in Q1, that 2027 revenue will more than make up for the 2026 deferral, and that launch coverage is expected to be about 40% of U.S. lives at launch and around 50% by year-end. They also said the company will prioritize new users if capacity is tight and that existing iLet users may convert to Mint over time, especially because Mint reimbursement could be materially more lucrative than DME iLet supply revenue.
The bull case is that Beta Bionics has a record-growth core business, a strong balance sheet, and a major new product in Mint that management believes can expand the category. Management sounded confident that Mint will be commercially meaningful in 2027, that pharmacy coverage will be broad, and that 3D Intelligence, type 2 expansion, and fully closed loop could add more growth vectors.
The main risks are execution and regulatory timing: 3D Intelligence was delayed by FDA questions, Mint manufacturing is not yet fully up and running, and management acknowledged 2027 Mint margins will be dilutive at first. There is also uncertainty around how much Mint demand turns into deferral versus true incremental adoption, and management said the mix of existing iLet users, new users, and uninsured patients is still hard to quantify precisely.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 44.5%
- Shares Outstanding
- 44.99M
- Float Shares
- 20.04M
of shares held by institutions
138 13F filers
Buy/sell ratio 0.31. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eventide Asset Management, LLC | 6.25M | ▲ 308.19K |
| Soleus Capital Management, L.P. | 4.39M | ▲ 39.21K |
| Morgan Stanley | 4.27M | ▲ 39.19K |
| Sands Capital Alternatives, LLC | 3.71M | 0 |
| Blackrock, Inc. | 3.34M | ▲ 301.58K |
| Point72 Asset Management, L.P. | 2.25M | ▼ 270.36K |
| Vanguard Group Inc | 2.22M | ▲ 2.05K |
| Jpmorgan Chase & Co | 1.87M | ▲ 1.17M |
| Vanguard Capital Management LLC | 1.78M | ▲ 54.37K |
| Vestal Point Capital, LP | 1.60M | ▼ 611.52K |
| Rtw Investments, LP | 1.50M | ▼ 500.00K |
| Deerfield Management Company, L.P. | 1.32M | 0 |
Held by 165 ETFs
Biggest fund positions in BBNX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Hopman Mark | other | 775 |
| Nov 16, 26 | Hopman Mark | sell | 775 |
| Nov 16, 26 | Hopman Mark | other | 775 |
| Nov 11, 26 | Feider Stephen | other | 8,874 |
| Nov 11, 26 | Feider Stephen | sell | 8,874 |
| Nov 11, 26 | Feider Stephen | other | 8,874 |
| Nov 9, 26 | Feider Stephen | other | 744 |
| Nov 9, 26 | Feider Stephen | sell | 744 |
| Nov 9, 26 | Feider Stephen | other | 744 |
| Nov 5, 26 | Feider Stephen | other | 382 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BBNX coverage
Recent articles, reports, and earnings notes.
No research on BBNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BBNX report →BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas
zacks.com · Nov 17
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
globenewswire.com · Nov 16
Beta Bio: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 9
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX
globenewswire.com · Nov 3
BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
prnewswire.com · Nov 3
BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights
businesswire.com · Nov 3
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX
globenewswire.com · Nov 3
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026
businesswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.